ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
1.210
-0.020 (-1.63%)
Nov 20, 2024, 4:00 PM EST - Market closed
ALX Oncology Holdings Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
72
Market Cap
63.82M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Celularity | 42.69M |
Cryo-Cell International | 31.84M |
electroCore | 23.33M |
Forian | 19.71M |
Cue Biopharma | 9.53M |
InspireMD | 6.82M |
Pheton Holdings | 572.29K |
Monogram Technologies | 365.00K |
ALXO News
- 7 days ago - ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer - GlobeNewsWire
- 13 days ago - ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 19 days ago - ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024 - GlobeNewsWire
- 2 months ago - ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations - Seeking Alpha
- 3 months ago - ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors - GlobeNewsWire
- 4 months ago - ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer - GlobeNewsWire
- 4 months ago - ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer - GlobeNewsWire
- 5 months ago - ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation - Seeking Alpha